Selenium and vitamin are E not promising, but both the Prostate Cancer Prevention Trial and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial showed a 20% to 25% reduction in the incidence of prostate cancer from two different 5-alpha-reductase inhibitors, finasteride (Proscar) and dutasteride (Avodart).
The development of targeted molecular therapies offers new avenues for combining pharmacologic and surgical therapies in the treatment of advanced renal cell carcinoma.
Receiving a diagnosis of prostate cancer is accompanied by significantly increased risks of suicide and cardiovascular death, according to recent results of a U.S. population-based cohort study.
The first-ever presentation of phase III data from the investigational taxane cabazitaxel showed a 30% improvement in survival in men with metastatic castration-resistant prostate cancer.
Researchers for the Urinary Incontinence Treatment Network found that the minimum important difference for the Urogenital Distress Inventory was –35 to –45 points in patients with urge urinary incontinence.
Enough evidence has linked ADT to cardiovascular events and diabetes to warrant a recent science advisory compiled by AUA, the American Heart Association, American Cancer Society, and American Society for Radiation Oncology.
Evidence that percutaneous tibial nerve stimulation is an effective, drug-free treatment for overactive bladder is mounting. A double-blind, sham-controlled, multicenter trial showed a response rate of about 50% in patients who have struggled with symptoms for a decade.
The following pages feature products and services from manufacturers that are exhibiting at the American Urological Association annual meeting in San Francisco. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.
Surgeons who automatically consider radical nephrectomy for small renal tumors are doing their patients a disservice. Data from Memorial Sloan-Kettering Cancer Center and other centers suggest that partial nephrectomy is more appropriate, especially for smaller tumors.
A major cause of concern among urologists and other physicians with large Medicare patient practices is a provision in the new law that will establish a new Independent Payment Advisory Board that is charged with reducing the per capita rate of growth in Medicare spending indefinitely.
Studies are revealing a genetic basis for stress urinary incontinence and pelvic organ prolapse and are showing that the two conditions are more disparate than previously thought.
The American Association of Clinical Urologists has always been the political voice for organized urology and believes that urologists themselves must speak to elected officials directly.
Caris Life Sciences (Irving, TX) has announced the launch of its urologic pathology practice, available through its subsidiary Caris Diagnostics.
Blue Shield of California now covers the Renessa System (Novasys Medical, Inc., Newark, CA) treatment for non-pregnant women diagnosed with moderate to severe stress urinary incontinence who are unable or unwilling to undergo surgery.
Cancer often leads to significant and long-term disruption in sexual function and intimacy, regardless of the type of cancer or how far along the patient is in the treatment plan, say researchers from Duke Clinical Research Institute, Durham, NC.
Men with prostate cancer are at increased risk of thromboembolism, particularly those receiving hormone therapy, according to a recent study.
The American Board of Medical Specialties, which oversees the certification of physician specialists in the United States, has appointed Gerald H. Jordan, MD, to its board.
Hannelore Heemers, PhD, has been appointed assistant professor in the department of urology and member of the genitourinary program at Roswell Park Cancer Institute in Buffalo, NY.
Beaumont Hospitals, Royal Oak, MI, has opened a new Women's Urology Center that the hospital says is the first center in the Midwest dedicated and designed exclusively for women's urological care and sexual health.
Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man, according to recently published research.
Although the mandatory compliance date for implementation is October 1, 2013, you'll need to accomplish much between now and then to make documentation and diagnosis reporting as seamless as possible.
It is known that penile implants coated or impregnated with antibiotics produce lower short-term, post-surgical infection rates than implants not treated with antibiotics, but researchers from several institutions are now reporting lower infection rates over the long term, as well.
A form of testosterone replacement therapy that uses implantable testosterone pellets (Testopel) is a viable alternative to existing treatments for hypogonadism, with a number of practical advantages for patients.
The addition of a short course of hormone therapy to radiation improves outcomes for patients with intermediate-risk, early-stage prostate cancer.
Finding a solution would seem to be a core issue for those interested in reforming a health care system in which Medicare is such a core component.
However you decide to market and promote your practice, you will want to measure the impact and results of your efforts.
New urology products and services on the horizon.
Newly available urology products and services.